Access our complete H1/H2 industry report: Six Months In: A 2026 Progress Check on Pharma Dealmaking, Access and CommercializationAs the pharmaceutical industry crosses the midpoint of 2026, the landscape is defined by an accelerating dealmaking environment, fast-moving shifts in how patients access and pay for therapies and a widening gap in patient affordability. The series started when PC asked a set of experts across different corners of the pharma commercial landscape to lay out what they expected the year ahead to bring. Amy Niles, chief mission officer at the Patient Advocate Foundation, laid out what she was watching on patient access and affordability. And, Emma Banks, CEO of ramarketing, mapped out how commercial strategy and AI adoption would take shape. And running underneath all of it is a commercial strategy landscape still working out where AI genuinely changes the job and where human judgment still has to close the gap.